gene	chromosome	position	ref	alt	source	drug	cancerType	level	hmfLevel	evidenceType	significance	hmfResponse
BRAF	7	140453136	A	C	oncoKb	Vemurafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	C	oncoKb	Dabrafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	T	oncoKb	Vemurafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	T	oncoKb	Dabrafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	TT	oncoKb	Vemurafenib	Melanoma	1	A	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	TT	oncoKb	Dabrafenib + Trametinib	Melanoma	1	A	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CT	oncoKb	Vemurafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CT	oncoKb	Dabrafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CG	oncoKb	Vemurafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CG	oncoKb	Dabrafenib	Non-Small Cell Lung Cancer	2A	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	C	cgi	Vemurafenib	Cutaneous melanoma	NCCN guidelines	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	C	cgi	Vemurafenib	Non-small cell lung	NCCN guidelines	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	T	cgi	Dabrafenib	Non-small cell lung	NCCN guidelines	B	Predictive	Responsive	Responsive
BRAF	7	140453136	A	T	cgi	Dabrafenib	Cutaneous melanoma	FDA guidelines	A	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	TT	cgi	Vemurafenib	Non-small cell lung	NCCN guidelines	B	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	TT	cgi	Vemurafenib + Cobimetinib	Cutaneous melanoma	FDA guidelines	A	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CT	cgi	Trametinib	Cutaneous melanoma	Case report	C	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CT	cgi	Dabrafenib	Cutaneous melanoma	Early trials	C	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CG	cgi	Trametinib	Cutaneous melanoma	Case report	C	Predictive	Responsive	Responsive
BRAF	7	140453136	AC	CG	cgi	Dabrafenib	Cutaneous melanoma	Early trials	C	Predictive	Responsive	Responsive
BRAF	7	140453136	A	T	civic	Vemurafenib	Ovarian Cancer	B	B	Predictive	Sensitivity	Responsive
BRAF	7	140453136	A	T	civic	Vemurafenib	Skin Melanoma	A	A	Predictive	Sensitivity	Responsive
BRAF	7	140453136	AC	TT	civic	Vemurafenib	Melanoma	B	B	Predictive	Sensitivity	Responsive
BRAF	7	140453136	AC	TT	civic	Dabrafenib + Trametinib	Melanoma	B	B	Predictive	Sensitivity	Responsive
